Boryung Pharmaceutical held a ceremony on April 23 to mark the completion of a new production complex in Yesan, South Chungcheong Province. The production complex, built with an investment of 160 billion won on some 145,097 square meters of land, is expected to play a pivotal role in Boryung Pharmaceutical's global expansion.
The first basement, five floors above ground and a total floor area of about 28,551 square meters will be built with solid formulation and anti-cancer injection facilities. The new plant is a one-stop package from production and packaging to delivery, and is a smart factory that is equipped with an electronic automation system.
By delegating authority to facilities equipped with self-communication functions, the company has established a manufacturing environment that operates on its own. In addition, the data generated within the plant are linked to production and the management systems such as the MES (Manufacturing Execution System) and Enterprise Resource Planning (ERP) and optimized for factory conditions.
Through the establishment of Smart Factory, production and logistics processing capabilities have also increased about three times compared to the current Ansan plant.
It is built with a structure that can be expanded to include five times more solid formulation, three times more anti-cancer drugs and other production facilities, which have the advantage of further increasing the operation rate in the future. Above all, it is expected to be a huge help to advance into foreign markets by securing hardware and quality of global level (cGMP and EUGMP).
"The Yesan production complex will be a new mecca for the healthcare industry that will lead the nation's future economy, beyond protecting and realizing the 'healthy and happy lives of mankind,'" said Ahn Jae-hyun, CEO of Boryeong Pharmaceutical.